Publicaciones en las que colabora con Daniel Castellano-Gauna (12)

2022

  1. A phase II randomised trial of abiraterone acetate plus prednisone in combination with docetaxel or docetaxel plus prednisone after disease progression to abiraterone acetate plus prednisone in patients with metastatic castration-resistant prostate cancer: The ABIDO-SOGUG trial

    European Journal of Cancer, Vol. 175, pp. 110-119

  2. BlaDimiR: A Urine-based miRNA Score for Accurate Bladder Cancer Diagnosis and Follow-up

    European Urology

  3. Clinical Factors Associated With Long-Term Benefit in Patients With Metastatic Renal Cell Carcinoma Treated With Axitinib: Real-World AXILONG Study

    Clinical Genitourinary Cancer, Vol. 20, Núm. 1, pp. 25-34

2020

  1. Re: Inhibition of a G9a/DNMT Network Triggers Immune-Mediated Bladder Cancer Regression

    Journal of Urology

2019

  1. CDK4/6 inhibitor as a novel therapeutic approach for advanced bladder cancer independently of RB1 status

    Clinical Cancer Research, Vol. 25, Núm. 1, pp. 390-402

  2. Inhibition of a G9a/DNMT network triggers immune-mediated bladder cancer regression

    Nature Medicine

2017

  1. BMP4 induces M2 macrophage polarization and favors tumor progression in bladder cancer

    Clinical Cancer Research, Vol. 23, Núm. 23, pp. 7388-7399

  2. Opposing roles of PIK3CA gene alterations to EZH2 signaling in non-muscle invasive bladder cancer

    Oncotarget, Vol. 8, Núm. 6, pp. 10531-10542

2015

  1. A Polycomb-mir200 loop regulates clinical outcome in bladder cancer

    Oncotarget, Vol. 6, Núm. 39, pp. 42258-42275

  2. Analysis of the polycomb-related lncRNAs HOTAIR and ANRIL in bladder cancer

    Clinical Epigenetics, Vol. 7, Núm. 1

  3. PIK3CA gene alterations in bladder cancer are frequent and associate with reduced recurrence in non-muscle invasive tumors

    Molecular Carcinogenesis, Vol. 54, Núm. 7, pp. 566-576

2014

  1. In vivo disruption of an Rb-E2F-Ezh2 signaling loop causes bladder cancer

    Cancer Research, Vol. 74, Núm. 22, pp. 6565-6577